The advent of effective adjuvant therapies for patients with resected melanoma has highlighted the need to stratify patients based on risk of relapse given the cost and toxicities associated with treatment. Here we assessed circulating tumor DNA (ctDNA) to predict and monitor relapse in resected stage III melanoma.
Rebecca Lee, Dominic G. Rothwell, Richard A. Jackson, Nigel Smith, Stephen Q. Wong, Noel Kelso, George J. Burghel, Chelsee Hewitt, Harry S. Clarke, Jackie Mitchell, Kate Jones, Andrew Muinonen‐Martin, Samra Turajlic, Pippa Corrie, Richard Marais, Mark R. Middleton, Sarah‐Jane Dawson, Shahneen Sandhu, Caroline Dive, Paul Lorigan
Andy Muinonen-Martin, Rebecca Lee, Dominic G. Rothwell, Richard A. Jackson, Nigel Smith, Stephen Q. Wong, Noel Kelso, Chelsee Hewitt, Jackie Mitchell, Kate Jones, Samra Turajlic, Pippa Corrie, Richard Marais, Mark R. Middleton, Sarah‐Jane Dawson, Shahneen Sandhu, Caroline Dive, Paul Lorrigan
Wei Yen Chan, Jenny Lee, Ashleigh Stewart, Russell J. Diefenbach, Maria Gonzalez, Alexander M. Menzies, Christian U. Blank, Richard A Scolyer, Georgina V. Long, Helen Rizos
Russell J. Diefenbach, Jenny Lee, Alexander M. Menzies, Matteo S. Carlino, Georgina V. Long, Robyn P.M. Saw, Julie R. Howle, Andrew J. Spillane, Richard A Scolyer, Richard Kefford, Helen Rizos
Russell J. Diefenbach, Jenny Lee, Dario Strbenac, Jean Yang, Alexander M. Menzies, Matteo S. Carlino, Georgina V. Long, Andrew J. Spillane, Jonathan R. Stretch, Robyn P.M. Saw, John F. Thompson, Sydney Ch’ng, Richard A Scolyer, Richard Kefford, Helen Rizos
Discussion(0)
No comments yet. Be the first to comment.